Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical ...

A study led by Winship Cancer Institute of Emory University and Abramson Cancer Center of the University of Pennsylvania ...

Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a biotechnology company that designs and develops breakthrough medicines for patients through its powerful computational drug discovery ...

Background Heart failure (HF) guidelines recommend routine testing for iron deficiency (ID) and, for those with ID, ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

Morgan Stanley analyst Michael Ulz maintained a Hold rating on Vir Biotechnology (VIR – Research Report) today and set a price target of ...

An Austin biotech company is laying off a third of its staff following news that its primary drug candidate didn't produce ...

The global artificial intelligence in clinical trials market , valued at US$1.20 billion in 2023, is forecasted to grow at a ...

US-based Halia Therapeutics’ new therapy will be put to a six-month-long trial that will involve 60 patients with type 2 ...

A multidisciplinary team of University of Miami researchers studying factors associated with health outcomes and disease risk in the Hispanic community has received a $21 million grant from the ...

NXC-201 is a sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy. Initial data from Phase 1b/2 ex-U.S. study NEXICART-1 has demonstrated high complete response rates ...